BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

BioNTech (BNTX) has drawn fresh attention after recent share price moves, with the stock up around 9% over the past week and ...

After a period defined by its COVID-19 vaccine, BioNTech is reasserting its presence in the oncology arena. A recent regulatory milestone and a significant upgrade from a major investment bank are ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

Phase 1/2a trial of BNT324/DB-1311 in solid tumors showed a 32.4% unconfirmed objective response rate and 82.4% disease control rate. BNT324/DB-1311 showed a manageable safety profile across all ...

BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...